Cargando…

Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer

With the increasing incidence of colorectal cancer (CRC) and continued difficulty in treating it using immunotherapy, there is an urgent need to identify an effective immune-related biomarker associated with the survival and prognosis of patients with this disease. DNA methylation plays an essential...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Feng, Pei, Lijuan, Liu, Siyao, Lin, Yan, Han, Xinyin, Meng, Erhong, Wang, Xintong, Hong, Shuai, Wang, Dongliang, Liu, Feide, Fei, Yang, Wang, Guangda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273301/
https://www.ncbi.nlm.nih.gov/pubmed/34262597
http://dx.doi.org/10.3389/fgene.2021.684349
_version_ 1783721339590279168
author Chen, Feng
Pei, Lijuan
Liu, Siyao
Lin, Yan
Han, Xinyin
Meng, Erhong
Wang, Xintong
Hong, Shuai
Wang, Dongliang
Liu, Feide
Fei, Yang
Wang, Guangda
author_facet Chen, Feng
Pei, Lijuan
Liu, Siyao
Lin, Yan
Han, Xinyin
Meng, Erhong
Wang, Xintong
Hong, Shuai
Wang, Dongliang
Liu, Feide
Fei, Yang
Wang, Guangda
author_sort Chen, Feng
collection PubMed
description With the increasing incidence of colorectal cancer (CRC) and continued difficulty in treating it using immunotherapy, there is an urgent need to identify an effective immune-related biomarker associated with the survival and prognosis of patients with this disease. DNA methylation plays an essential role in maintaining cellular function, and changes in methylation patterns may contribute to the development of autoimmunity, aging, and cancer. In this study, we aimed to identify a novel immune-related methylated signature to aid in predicting the prognosis of patients with CRC. We investigated DNA methylation patterns in patients with stage II/III CRC using datasets from The cancer genome atlas (TCGA). Overall, 182 patients were randomly divided into training (n = 127) and test groups (n = 55). In the training group, five immune-related methylated CG sites (cg11621464, cg13565656, cg18976437, cg20505223, and cg20528583) were identified, and CG site-based risk scores were calculated using univariate Cox proportional hazards regression in patients with stage II/III CRC. Multivariate Cox regression analysis indicated that methylated signature was independent of other clinical parameters. The Kaplan–Meier analysis results showed that CG site-based risk scores could significantly help distinguish between high- and low-risk patients in both the training (P = 0.000296) and test groups (P = 0.022). The area under the receiver operating characteristic curve in the training and test groups were estimated to be 0.771 and 0.724, respectively, for prognosis prediction. Finally, stratified analysis results suggested the remarkable prognostic value of CG site-based risk scores in CRC subtypes. We identified five methylated CG sites that could be used as an efficient overall survival (OS)-related biomarker for stage II/III CRC patients.
format Online
Article
Text
id pubmed-8273301
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82733012021-07-13 Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer Chen, Feng Pei, Lijuan Liu, Siyao Lin, Yan Han, Xinyin Meng, Erhong Wang, Xintong Hong, Shuai Wang, Dongliang Liu, Feide Fei, Yang Wang, Guangda Front Genet Genetics With the increasing incidence of colorectal cancer (CRC) and continued difficulty in treating it using immunotherapy, there is an urgent need to identify an effective immune-related biomarker associated with the survival and prognosis of patients with this disease. DNA methylation plays an essential role in maintaining cellular function, and changes in methylation patterns may contribute to the development of autoimmunity, aging, and cancer. In this study, we aimed to identify a novel immune-related methylated signature to aid in predicting the prognosis of patients with CRC. We investigated DNA methylation patterns in patients with stage II/III CRC using datasets from The cancer genome atlas (TCGA). Overall, 182 patients were randomly divided into training (n = 127) and test groups (n = 55). In the training group, five immune-related methylated CG sites (cg11621464, cg13565656, cg18976437, cg20505223, and cg20528583) were identified, and CG site-based risk scores were calculated using univariate Cox proportional hazards regression in patients with stage II/III CRC. Multivariate Cox regression analysis indicated that methylated signature was independent of other clinical parameters. The Kaplan–Meier analysis results showed that CG site-based risk scores could significantly help distinguish between high- and low-risk patients in both the training (P = 0.000296) and test groups (P = 0.022). The area under the receiver operating characteristic curve in the training and test groups were estimated to be 0.771 and 0.724, respectively, for prognosis prediction. Finally, stratified analysis results suggested the remarkable prognostic value of CG site-based risk scores in CRC subtypes. We identified five methylated CG sites that could be used as an efficient overall survival (OS)-related biomarker for stage II/III CRC patients. Frontiers Media S.A. 2021-06-28 /pmc/articles/PMC8273301/ /pubmed/34262597 http://dx.doi.org/10.3389/fgene.2021.684349 Text en Copyright © 2021 Chen, Pei, Liu, Lin, Han, Meng, Wang, Hong, Wang, Liu, Fei and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Chen, Feng
Pei, Lijuan
Liu, Siyao
Lin, Yan
Han, Xinyin
Meng, Erhong
Wang, Xintong
Hong, Shuai
Wang, Dongliang
Liu, Feide
Fei, Yang
Wang, Guangda
Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer
title Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer
title_full Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer
title_fullStr Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer
title_full_unstemmed Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer
title_short Identification of a Novel Immune-Related CpG Methylation Signature to Predict Prognosis in Stage II/III Colorectal Cancer
title_sort identification of a novel immune-related cpg methylation signature to predict prognosis in stage ii/iii colorectal cancer
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273301/
https://www.ncbi.nlm.nih.gov/pubmed/34262597
http://dx.doi.org/10.3389/fgene.2021.684349
work_keys_str_mv AT chenfeng identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT peilijuan identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT liusiyao identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT linyan identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT hanxinyin identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT mengerhong identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT wangxintong identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT hongshuai identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT wangdongliang identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT liufeide identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT feiyang identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer
AT wangguangda identificationofanovelimmunerelatedcpgmethylationsignaturetopredictprognosisinstageiiiiicolorectalcancer